Literature DB >> 11289105

Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A.

A Kadambi1, C Mouta Carreira, C O Yun, T P Padera, D E Dolmans, P Carmeliet, D Fukumura, R K Jain.   

Abstract

Unlike vascular endothelial growth factor (VEGF)-A, the effect of VEGF-C on tumor angiogenesis, vascular permeability, and leukocyte recruitment is not known. To this end, we quantified in vivo growth and vascular function in tumors derived from two VEGF-C-overexpressing (VC+) and mock-transfected cell lines (T241 fibrosarcoma and VEGF-A-/- embryonic stem cells) grown in murine dorsal skinfold chambers. VC+ tumors grew more rapidly than mock-transfected tumors and exhibited parallel increases in tumor angiogenesis. Furthermore, VEGF-C overexpression elevated vascular permeability in T241 tumors, but not in VEGF-A-/- tumors. Surprisingly, unlike VEGF-A, VEGF-C did not increase leukocyte rolling or adhesion in tumor vessels. Administration of VEGF receptor (VEGFR)-2 neutralizing antibody DC101 reduced vascular density and permeability of both VC+ and mock-transduced T241 tumors. These data suggest that VEGFR-2 signaling is critical for tumor angiogenesis and vascular permeability and that VEGFR-3 signaling does not compensate for VEGFR-2 blockade. An alternate VEGFR, VEGFR-1 or neuropilin-1, may modulate adhesion of leukocytes to tumor vessels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289105

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.

Authors:  Lee B Rivera; David Meyronet; Valérie Hervieu; Mitchell J Frederick; Emily Bergsland; Gabriele Bergers
Journal:  Cell Rep       Date:  2015-04-16       Impact factor: 9.423

3.  Angiopoietin-4 increases permeability of blood vessels and promotes lymphatic dilation.

Authors:  Cristina T Kesler; Ethel R Pereira; Cheryl H Cui; Gregory M Nelson; David J Masuck; James W Baish; Timothy P Padera
Journal:  FASEB J       Date:  2015-05-14       Impact factor: 5.191

4.  Measuring Vascular Permeability In Vivo.

Authors:  Eelco F J Meijer; James W Baish; Timothy P Padera; Dai Fukumura
Journal:  Methods Mol Biol       Date:  2016

Review 5.  Mesenchymal stem cells engineered for cancer therapy.

Authors:  Khalid Shah
Journal:  Adv Drug Deliv Rev       Date:  2011-06-29       Impact factor: 15.470

Review 6.  Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models.

Authors:  Dai Fukumura; Dan G Duda; Lance L Munn; Rakesh K Jain
Journal:  Microcirculation       Date:  2010-04       Impact factor: 2.628

Review 7.  Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.

Authors:  Dan G Duda; Rakesh K Jain; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

Review 8.  Potential therapeutic strategies for lymphatic metastasis.

Authors:  Bernadette M M Zwaans; Diane R Bielenberg
Journal:  Microvasc Res       Date:  2007-09-19       Impact factor: 3.514

Review 9.  Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.

Authors:  Yolanda Nesbeth; Jose R Conejo-Garcia
Journal:  Clin Dev Immunol       Date:  2010-11-07

10.  What brings pericytes to tumor vessels?

Authors:  Rakesh K Jain; Michael F Booth
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.